235 related articles for article (PubMed ID: 32628746)
1. NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat.
Azizi AA; Walker DA; Liu JF; Sehested A; Jaspan T; Pemp B; Simmons I; Ferner R; Grill J; Hargrave D; Driever PH; Evans DG; Opocher E;
Neuro Oncol; 2021 Jan; 23(1):100-111. PubMed ID: 32628746
[TBL] [Abstract][Full Text] [Related]
2. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
3. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program.
Dalla Via P; Opocher E; Pinello ML; Calderone M; Viscardi E; Clementi M; Battistella PA; Laverda AM; Da Dalt L; Perilongo G
Neuro Oncol; 2007 Oct; 9(4):430-7. PubMed ID: 17704361
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.
Kotch C; Avery R; Getz KD; Bouffet E; de Blank P; Listernick R; Gutmann DH; Bornhorst M; Campen C; Liu GT; Aplenc R; Li Y; Fisher MJ
Neuro Oncol; 2022 Aug; 24(8):1377-1386. PubMed ID: 35018469
[TBL] [Abstract][Full Text] [Related]
5. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
6. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.
Falzon K; Drimtzias E; Picton S; Simmons I
Br J Ophthalmol; 2018 Oct; 102(10):1367-1371. PubMed ID: 29343527
[TBL] [Abstract][Full Text] [Related]
7. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.
de Blank PMK; Fisher MJ; Liu GT; Gutmann DH; Listernick R; Ferner RE; Avery RA
J Neuroophthalmol; 2017 Sep; 37 Suppl 1(Suppl 1):S23-S32. PubMed ID: 28806346
[TBL] [Abstract][Full Text] [Related]
8. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1.
Trevisson E; Cassina M; Opocher E; Vicenzi V; Lucchetta M; Parrozzani R; Miglionico G; Mardari R; Viscardi E; Midena E; Clementi M
J Neurooncol; 2017 Sep; 134(2):279-287. PubMed ID: 28577031
[TBL] [Abstract][Full Text] [Related]
9. Manifestations and Treatment of Adult-onset Symptomatic Optic Pathway Glioma in Neurofibromatosis Type 1.
Mehlan J; Schüttauf F; Salamon JM; Kordes U; Friedrich RE; Mautner VF
Anticancer Res; 2019 Feb; 39(2):827-831. PubMed ID: 30711963
[TBL] [Abstract][Full Text] [Related]
10. Optic pathway glioma in children: does visual deficit correlate with radiology in focal exophytic lesions?
Aquilina K; Daniels DJ; Spoudeas H; Phipps K; Gan HW; Boop FA
Childs Nerv Syst; 2015 Nov; 31(11):2041-9. PubMed ID: 26277358
[TBL] [Abstract][Full Text] [Related]
11. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT
Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213
[TBL] [Abstract][Full Text] [Related]
12. Optic Pathway Gliomas in Neurofibromatosis Type 1.
Campen CJ; Gutmann DH
J Child Neurol; 2018 Jan; 33(1):73-81. PubMed ID: 29246098
[TBL] [Abstract][Full Text] [Related]
13. Optic Gliomas in Neurofibromatosis Type 1.
Parkhurst E; Abboy S
J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):334-338. PubMed ID: 27537249
[TBL] [Abstract][Full Text] [Related]
14. Neurofibromatosis type 1 and optic pathway glioma. A long-term follow-up.
Lama G; Esposito Salsano M; Grassia C; Calabrese E; Grassia MG; Bismuto R; Melone MA; Russo S; Scuotto A
Minerva Pediatr; 2007 Feb; 59(1):13-21. PubMed ID: 17301720
[TBL] [Abstract][Full Text] [Related]
15. Neurofibromatosis type 1 and sporadic optic gliomas.
Singhal S; Birch JM; Kerr B; Lashford L; Evans DG
Arch Dis Child; 2002 Jul; 87(1):65-70. PubMed ID: 12089128
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors of neurofibromatosis type 1-associated optic pathway gliomas in children].
Florent C; Beylerian M; Mairot K; Dambricourt L; André N; David T; Girard N; Audic F; Denis D
J Fr Ophtalmol; 2022 Feb; 45(2):173-184. PubMed ID: 34972579
[TBL] [Abstract][Full Text] [Related]
17. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.
King A; Listernick R; Charrow J; Piersall L; Gutmann DH
Am J Med Genet A; 2003 Oct; 122A(2):95-9. PubMed ID: 12955759
[TBL] [Abstract][Full Text] [Related]
18. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
Listernick R; Ferner RE; Liu GT; Gutmann DH
Ann Neurol; 2007 Mar; 61(3):189-98. PubMed ID: 17387725
[TBL] [Abstract][Full Text] [Related]
19. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort.
Blanchard G; Lafforgue MP; Lion-François L; Kemlin I; Rodriguez D; Castelnau P; Carneiro M; Meyer P; Rivier F; Barbarot S; Chaix Y;
Eur J Paediatr Neurol; 2016 Mar; 20(2):275-281. PubMed ID: 26774135
[TBL] [Abstract][Full Text] [Related]
20. Visual Outcomes After Treatment for Sporadic Optic Pathway Gliomas in Pediatric Patients: A Systematic Review.
Shlobin NA; Montgomery EY; Mohammad LM; Kandula V; Beestrum M; DeCuypere M; Lam SK
World Neurosurg; 2022 Aug; 164():436-449.e2. PubMed ID: 35430402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
